Atenolol v placebo or no treatment or v other antihypertensive drugs in essential hypertension at mean 4.6 years*
| Outcomes | Comparisons | Number of trials (number of patients) | Weighted event rates | RRR (95% CI) | NNT |
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; weighted event rates, RRR, RRI, NNT, NNH, and CI calculated from data in article using a fixed effects model. | |||||
| Myocardial infarction | Atenolol v placebo or no treatment | 4 (6392) | 7.2% v 7.2% | 1% (−19 to 17) | Not significant |
| Stroke | 7.2% v 8.2% | 15% (−1 to 28) | Not significant | ||
| Cardiovascular mortality | 8.0% v 8.0% | 1% (−18 to 17) | Not significant | ||
| RRI (CI) | NNH (CI) | ||||
| All cause mortality | 13.3% v 13.3% | 1% (−11 to 15) | Not significant | ||
| Myocardial infarction | Atenolol v other antihypertensive drugs | 4 (14 468) | 4.5% v 4.5% | 4% (−11 to 20) | Not significant |
| Stroke | 5.2% v 4.2% | 30% (12 to 50) | 100 (50 to 100) | ||
| Cardiovascular mortality | 5.4% v 4.4% | 16% (0 to 34) | 100 (100 to ∞) | ||
| All cause mortality | 5 (17 671) | 8.1% v 7.1% | 13% (2 to 25) | 100 (100 to ∞) | |